ProQR Therapeutics upgraded by Citigroup with a new price target
$PRQR
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $4.00
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/29/2025 | $5.00 | Outperform | Evercore ISI |
4/29/2025 | $8.00 | Overweight | Cantor Fitzgerald |
3/10/2025 | $4.00 | Neutral → Buy | Citigroup |
1/10/2025 | $15.00 | Outperform | Oppenheimer |
10/29/2024 | $6.00 → $14.00 | Outperform → Strong Buy | Raymond James |
11/8/2023 | $2.00 | Neutral → Buy | Chardan Capital Markets |
3/30/2023 | $1.50 → $5.00 | Mkt Perform → Mkt Outperform | JMP Securities |
12/22/2022 | $0.80 → $5.00 | Neutral → Overweight | Cantor Fitzgerald |